Annovis Bio, Inc. Profile Avatar - Palmy Investing

Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's di…

Biotechnology
US, Berwyn [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Annovis Bio, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ANVS's Analysis
CIK: 1477845 CUSIP: 03615A108 ISIN: US03615A1088 LEI: - UEI: -
Secondary Listings
ANVS has no secondary listings inside our databases.